Microbiome and Gut Dysbiosis
The gastrointestinal (GI) tract is the residence of trillions of microorganisms that include bacteria, archaea, fungi and viruses. The collective genomes of whole microbial communities (microbiota) integrate the gut microbiome. Up to 100 genera and 1000 distinct bacterial species were identified in digestive tube niches. Gut microbiomes exert permanent pivotal functions by promoting food digestion, xenobiotic metabolism and regulation of innate and adaptive immunological processes. Proteins, peptides and metabolites released locally and at distant sites trigger many cell signalling and pathways. This intense crosstalk maintains the host-microbial homeostasis. Diet, age, diet, stress and diseases cause increases or decreases in relative abundance and diversity bacterial specie of GI and other body sites. Studies in animal models and humans have shown that a persistent imbalance of gut’s microbial community, named dysbiosis, relates to inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), diabetes, obesity, cancer, cardiovascular and central nervous system disorders. Notably specific bacterial communities are promising clinical target to treat inflammatory and infectious diseases. In this context, intestinal microbiota transplantation (IMT) is one optional treatment for IBD, in particular to patients with recurrent Clostridium difficile-induced pseudo-membrane colitis. Here we discuss on recent discoveries linking whole gut microbiome dysbiosis to metabolic and inflammatory diseases and potential prophylactic and therapeutic applications of faecal and phage therapy, probiotic and prebiotic diets.
KeywordsMicrobiomes Metabolic and gastrointestinal diseases Probiotics Prebiotics Faecal therapy
We thank Aline Maria da Silva, João Carlos Setubal, Dan Waitzberg and colleagues of University of Sao Paulo and Clinical Hospital of Medical School for insights and productive discussions.
- Abedon ST (2014) Phage therapy: eco-physiological pharmacology. Scientifica 214:581639Google Scholar
- Alivisatos AP, Blaser MJ, Brodie EL, Chun M, Dangl JL, Donohue TJ, Dorrestein PC, Gilbert JA, Green JL, Jansson JK, Knight R, Maxon ME, McFall-Ngai MJ, Miller MF, Pollard KS, Ruby EG, Taha SA, Unified Microbiome Initiative Consortium (2015) A unified initiative to harness Earth’s microbiomes. Science 350(6260):507–508CrossRefPubMedGoogle Scholar
- Almonacid DE, Kraal L, Ossandon FJ, Budovskaya YV, Cardenas JP, Bik EM, Goddard AD, Richman J, Zachary S, Apte ZS (2017) 16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome. PLoS One 12(5):e0176555CrossRefPubMedPubMedCentralGoogle Scholar
- Brown CT, Sharon I, Thomas BC, Castelle CJ, Morowitz MJ, Banfield JF (2013b) Genome resolved analysis of a premature infant gut microbial community reveals a Varibaculum cambriense genome and a shift towards fermentation-based metabolism during the third week of life. Microbiome 1(1):30. https://doi.org/10.1186/2049-2618-1-30CrossRefPubMedPubMedCentralGoogle Scholar
- Costa FRC, Françozo MCS, Oliveira GG, Ignacio A, Castoldi A, Zamboni DS, Ramos SG, Câmara NO, Zoete MR, Palm NW, Flavell RA, Silva JS, Carlos D (2016) Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset. J Exp Med 213:1223–1239CrossRefPubMedPubMedCentralGoogle Scholar
- De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107:14691–14696CrossRefPubMedPubMedCentralGoogle Scholar
- Sampson TR, Saroj SD, Llewellyn AC, Tzeng YL, Weiss DS (2010) A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature 479:254–257Google Scholar
- Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, Miller SI (2015) Faecal microbial transplant effect on clinical outcomes and faecal microbiome in active Crohn’s disease. Inflamm Bowel Dis 21(3):556–563CrossRefPubMedPubMedCentralGoogle Scholar
- Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in subjects with metabolic syndrome. Gastroenterology (4):913–916Google Scholar